Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, October 3, 2026

Back to today

From X

@calvinblissett 1 click

Calvin Blissett on X

$PAHC: 9x cash flow. 26% ROE Animals have to be healthy whether the economy is good or bad, and livestock producers have an economic incentive to spend money on products that reduce mortality, improve feed conversion, increase yield or prevent disease. 22% Adj EBITDA margin. JPM $55 PT. The company operates through the following business divisions: Animal Health division manufactures and sells animal health products such as antibacterial, anticoccidials, nutritional specialty products and vaccines used in the animal health industry to treat or to prevent bacterial diseases to improve the animal’s health. Mineral Nutrition division manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds. Performance Products division manufactures and markets various specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The most tangible new initiative is the planned closure of Chicago Heights, Illinois. Phibro acquired the facility as part of the Zoetis deal, reviewed its manufacturing network and decided it no longer made economic sense to keep the facility open. Production is expected to cease in summer 2027, affecting roughly 100 employees. Production will be shifted to other Phibro facilities and selected third-party manufacturers. Phibro Animal Health Corporation Management says the point is straightforward: align manufacturing capacity with future needs, improve efficiency and strengthen competitiveness. Phibro Animal Health Corporation The company expects approximately $10m of one-time cash costs and about $10m of capex, with eventual annual EBITDA benefit estimated around $15–20m, largely from FY2028 onward Regulatory optionality: Brazil virginiamycin One of the most interesting hidden catalysts is virginiamycin in Brazil. FY2027 guidance assumes only minimal sales because Phibro has not yet obtained the required therapeutic indications. FY2026 virginiamycin sales in Brazil were roughly $27m. Management explicitly said a favorable regulatory result could therefore provide modest upside to guidance.
@calvinblissett 1 click

Calvin Blissett on X

$FSBW: Bought Pacific West Bank in August for 30m. Exp +7.5% EPS growth in 2027 due to this. PWBK has a 92% deposit mix NOT CDs. (attractive b/c lower cost). First Bancorp a bit cyclical due to home lending, consistent double digit ROE, conservative way to play eventual housing rebound. The problem was not that Pacific West had no franchise. It had a recognizable Portland commercial-banking niche, a relatively attractive deposit base, and specialized relationships with SMBs, nonprofits, professional-services businesses and digital partners. The problem was scale. Management acknowledged that Pacific West's size and market position made both organic and strategic growth difficult, while the cost and complexity of running a regulated community bank had risen materially after 2008 and 2020.

Investor Letters

All letters
OPRX · long

Optimizerx CORP

OptimizeRx, OPRX, trades 30% below its February 2025 writeup despite becoming a stronger company.

OPRX $159M
Value Investors Club 2 clicks

Who Really Runs Tidewater (TDW)?

Tidewater CEO Quintin Kneen’s 2024 stock trades and board activity follow GulfMark’s bankruptcy, Tidewater’s merger and TDW’s 485%…

TDW $4.2B
Cannibal Stocks

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 218

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.